CRISPR Therapeutics AG CRSP 深 沪
等待开盘 01-28 09:30:00 美东时间
54.26
-0.390
-0.71%
华盛通- 最 高56.69
- 今 开55.50
- 成交量 135.71万股
- 最 低 53.57
- 昨 收 54.65
- 总市值 51.71亿
- 52周最高 78.48
- 市盈率 静 --
- 换手率 1.42%
- 52周最低 30.04
- 委 比 -31.67%
- 总股本 9530.02万
- 历史最高 220.20
- 量 比 0.64
- 振 幅 5.71%
- 历史最低 13.50
- 每 手 1
- 风险率 10.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cathie Wood's Favorite Biotech Stock Is Under Pressure Amid Insider Sales And Slow Revenue Growth: Momentum Score Drops
Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core products.
01-27 17:33
Not Just for Medical Inquiries: AI Healthcare Is Becoming the Next Golden Track
TradingKey - Artificial intelligence is reshaping the healthcare industry. This is not only a systemic change driven by technology but also represents a new round of investment opportunities for long-term value revaluation.
01-16 13:46
FDA放宽细胞与基因疗法CMC要求
美国食品药品监督管理局（FDA）提出在化学、生产和控制（chemistry， manufacturing and control，CMC）方面给予细胞与基因...
01-13 00:00
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
CRISPR Therapeutics outlined its strategic priorities and milestones for 2026, highlighting the continued commercialization of CASGEVY, pipeline advancements across hemoglobinopathies, cardiovascular diseases, and autoimmune conditions, and the initiation of multiple clinical trials. The company emphasized its strong financial position with $2 billion in cash and its diversified gene-editing and siRNA platforms supporting multi-billion-dollar pot...
01-12 13:36
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
CRISPR Therapeutics宣布其高级管理团队将在2026年1月12日参加第44届J.P. Morgan Healthcare Conference，介绍公司进展。公司简介：CRISPR Therapeutics是基因编辑领域的领导者，开发了世界上首个获批的CRISPR疗法CASGEVY®，用于治疗镰状细胞病和地中海贫血。公司通过SyNTase™平台推进多样化的治疗管线，并与Vertex Pharmaceuticals等领先企业合作，扩展其影响力。
01-05 13:30
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /PRNewswire/ -- Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by 2032, pow...
01-03 02:29
Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the genomic revolution.
01-01 06:06
Cathie Wood invests heavily in gene-editing companies, offloads $30 million worth Tesla stock
Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting holdings in Tesla (TSLA) and space-launch operator Rocket Lab (RKLB). Ark load...
2025-12-29 21:15
美股大行评级 | 潜在涨幅63.56%！拜玛林制药获Truist Securities升目标价至100美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持拜玛林制药"买入"评级，目标价从80美元升至100美元；HC Wainwright & Co.：维持Savara"买入"评级，目标价从8美元升至10美元
2025-12-24 11:17
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80 price target.
2025-12-23 22:03
